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pared to active controls. Meta-analyses did not find a dif-
ference between rofecoxib and celecoxib in broad safety
measures.
CONCLUSION: Caveats to this analysis include the po-
tential for selection and instrument bias. The two coxibs
show comparable overall efficacy and safety. However,
caution is advised in applying the results of aggregate anal-
yses at the individual patient level. Since the safety profiles
for the coxibs are somewhat different, arthritis treatment
should be individualized based on patient co-morbidities.
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OBJECTIVES: To measure quality of life and health-care
utilization related to osteoarthritis and to understand the
relationship among different parameters.
METHODS: 245 patients with osteoarthrosis (176 fe-
male) of mean age 64 years were recruited within a mus-
culoskeletal study in both primary care and rheumatol-
ogy outpatient settings in Hungary in 1999 and 2000.
Patients filled in both the generic EQ-5D quality-of-life
questionnaire and the disease-specific WOMAC ques-
tionnaire and reported resource utilization. Mean quality-
of-life and health-care-utilization values were reported
and correlation coefficients between different measure-
ments were analyzed.
RESULTS: Average EQ-5D index, EQ-5Dvas, WOMAC
(pain (A), stiffness (B), physical function (C)) scores were
0.42, 49.18, 9.28, 3.87, 36.32 respectively. Average an-
nual number of physiotherapy and spa treatment sessions
were 33.32 and 9.88, respectively. Average number of
GP and specialist visits were 31.4 and 8.54 annually. Pa-
tients spent a mean of nine days in hospital and they
spent 12.5 days in bed due to osteoarthritis. Active pa-
tients spent a mean of 6.7 days on sick leave. Statistically
significant correlation was observed between the follow-
ing: EQ-5D index and EQ-5Dvas; EQ-5D index and
WOMAC C; EQ-5Dvas and WOMAC C; days in bed
and EQ-5D index; days in bed and EQ-5Dvas; days in
bed and WOMAC C. Corresponding correlation coeffi-
cients were: 0.35; 0.59; 0.33; 0.35; 0.17; 0.24; re-
spectively (p  .01).
CONCLUSIONS: Results showed that osteoarthritis
leads to substantial loss in quality of life, important direct
medical costs, and substantial productivity loss among
active patients.
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OBJECTIVE: In order to assess the impact of interven-
tion programs to be implemented, a baseline assessment
of the burden of illness for arthritis is needed. Nearly one
third of Philadelphians receive their medical care through
Medicaid. To be representative of the population we
serve, we therefore set out to measure the incidence and
impact of arthritis in an inner city, Medicaid managed-
care population.
METHODS: We identified members continuously en-
rolled (per HEDIS definitions) during 1999 with paid
claims reflecting diagnoses indicative of arthritis. Primary
through quaternary diagnoses for arthritis (ICD-9CM
codes 095.6, 095.7, 095.8, 099.3, 136.1, 274, 277.2, 287.0,
344.6, 353.0, 354.0, 355.5, 357.1, 390, 391, 437.4,
443.0, 446, 447.6, 696.0, 710–716, 719.0, 719.2–719.9,
720–721, 725–727, 728.0–728.3, 728.6–728.9, 729.0–
729.1, and 729.4) were used to determine incidence. To-
tal amounts paid per claim were tallied. Arthritis-related
drugs were those defined as AHFS classes 12:20.00,
28:08.04, 28:08.08 and unclassified arthritis related agents.
Members’ demographic data was also obtained.
RESULTS: From a cohort of 73,948 members, we identi-
fied 8197 (11.1%) individuals with a medical claim for
arthritis. Females comprised 77.0% (1744) of these mem-
bers, greater than the norm for this population (p  .05).
The average age was 53.8 years. This population with ar-
thritis was composed of 46.8% African-Americans,
23.2% Caucasians, 23.7% Latinos, and 3.0% Asian-
Americans. Medical claims and arthritis-related drug
costs for this population totaled $5,328,406 ($650 per
identified member).
CONCLUSION: Effects of interventions cannot be mea-
sured until baseline information is assessed. It is hoped
that along with the data gathered here, an intervention
can be implemented citywide, the effects of which can be
measured. The diversity of Philadelphia’s population
should allow for differences that might exist among eth-
nic groups to be demonstrated. Managed care payers are
also responsible for drug expenditures. The costs for
some of these products are presented herein.
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OBJECTIVES: to estimate the cost-effectiveness of cele-
coxib 0,2 g bid vs. diclofenac 75 mg bid in rheumatoid
arthritis (RA) patients in Poland and to identify whether
and to what extent celecoxib represents good use of
health-service resources.
METHODS: A decision analytic model in the Polish
